{"id":"https://openalex.org/W2044656399","doi":"https://doi.org/10.1159/000314352","title":"Medical Treatment of Cushing\u2019s Disease: Somatostatin Analogues and Pasireotide","display_name":"Medical Treatment of Cushing\u2019s Disease: Somatostatin Analogues and Pasireotide","alternate_titles":[],"publication_year":2010,"publication_date":"2010-09-10","ids":{"openalex":"https://openalex.org/W2044656399","doi":"https://doi.org/10.1159/000314352","mag":"2044656399","pmid":"https://pubmed.ncbi.nlm.nih.gov/20829632"},"language":"en","primary_location":{"id":"doi:10.1159/000314352","doi":"https://doi.org/10.1159/000314352","is_oa":false,"landing_page_url":"https://doi.org/10.1159/000314352","pdf_url":null,"source":{"id":"https://openalex.org/S84102376","display_name":"Neuroendocrinology","issn_l":"0028-3835","issn":["0028-3835","1423-0194"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310317820","host_organization_name":"Karger Publishers","host_organization_lineage":["https://openalex.org/P4310317820"],"host_organization_lineage_names":["Karger Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neuroendocrinology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2044656399"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5021628357","display_name":"Alberto M Pedroncelli","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Alberto M. Pedroncelli","raw_affiliation_strings":["Novartis Pharma AG, Basle, Switzerland. alberto.pedroncelli@novartis.com","Novartis Pharma AG, Basle, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharma AG, Basle, Switzerland. alberto.pedroncelli@novartis.com","institution_ids":["https://openalex.org/I1283582996"]},{"raw_affiliation_string":"Novartis Pharma AG, Basle, Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5021628357"],"corresponding_institution_ids":["https://openalex.org/I1283582996"],"apc_list":null,"apc_paid":null,"fwci":2.4957,"has_fulltext":false,"cited_by_count":40,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.88622346,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":86,"max":98},"biblio":{"volume":"92","issue":"Suppl. 1","first_page":"120","last_page":"124"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10832","display_name":"Pituitary Gland Disorders and Treatments","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10832","display_name":"Pituitary Gland Disorders and Treatments","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10754","display_name":"Neuroendocrine Tumor Research Advances","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11054","display_name":"Adrenal and Paraganglionic Tumors","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cushing-disease","display_name":"Cushing's disease","score":1.0},{"id":"https://openalex.org/keywords/pasireotide","display_name":"pasireotide","score":0.9729999899864197},{"id":"https://openalex.org/keywords/somatostatin-analogs","display_name":"somatostatin analogues","score":0.9980000257492065},{"id":"https://openalex.org/keywords/somatostatin-receptor-5","display_name":"somatostatin receptor 5","score":0.8029999732971191},{"id":"https://openalex.org/keywords/octreotide","display_name":"octreotide","score":0.8539999723434448},{"id":"https://openalex.org/keywords/urinary-free-cortisol","display_name":"urinary free cortisol","score":0.8299999833106995},{"id":"https://openalex.org/keywords/cabergoline","display_name":"cabergoline","score":0.921999990940094},{"id":"https://openalex.org/keywords/ketoconazole","display_name":"ketoconazole","score":0.972000002861023}],"concepts":[{"id":"https://openalex.org/C2779371878","wikidata":"https://www.wikidata.org/wiki/Q3896970","display_name":"Pasireotide","level":5,"score":0.9890251755714417},{"id":"https://openalex.org/C2776810848","wikidata":"https://www.wikidata.org/wiki/Q1947304","display_name":"Cushing's disease","level":3,"score":0.8311662077903748},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.753169059753418},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.7279393672943115},{"id":"https://openalex.org/C2776297358","wikidata":"https://www.wikidata.org/wiki/Q407166","display_name":"Somatostatin","level":2,"score":0.6904592514038086},{"id":"https://openalex.org/C2777433750","wikidata":"https://www.wikidata.org/wiki/Q189580","display_name":"Acromegaly","level":4,"score":0.6525359749794006},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6331329345703125},{"id":"https://openalex.org/C2781025020","wikidata":"https://www.wikidata.org/wiki/Q419935","display_name":"Octreotide","level":3,"score":0.5517402291297913},{"id":"https://openalex.org/C80115893","wikidata":"https://www.wikidata.org/wiki/Q2067077","display_name":"Somatostatin receptor","level":3,"score":0.5327109694480896},{"id":"https://openalex.org/C2780546910","wikidata":"https://www.wikidata.org/wiki/Q185690","display_name":"Adrenocorticotropic hormone","level":3,"score":0.49795055389404297},{"id":"https://openalex.org/C2777428134","wikidata":"https://www.wikidata.org/wiki/Q272741","display_name":"Adenoma","level":2,"score":0.4220733046531677},{"id":"https://openalex.org/C71315377","wikidata":"https://www.wikidata.org/wiki/Q11364","display_name":"Hormone","level":2,"score":0.3056384325027466},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.1757352650165558},{"id":"https://openalex.org/C2984496839","wikidata":"https://www.wikidata.org/wiki/Q29956617","display_name":"Growth hormone","level":3,"score":0.0963854193687439}],"mesh":[{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010911","descriptor_name":"Pituitary Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D013004","descriptor_name":"Somatostatin","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D013004","descriptor_name":"Somatostatin","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D047748","descriptor_name":"Pituitary ACTH Hypersecretion","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1159/000314352","doi":"https://doi.org/10.1159/000314352","is_oa":false,"landing_page_url":"https://doi.org/10.1159/000314352","pdf_url":null,"source":{"id":"https://openalex.org/S84102376","display_name":"Neuroendocrinology","issn_l":"0028-3835","issn":["0028-3835","1423-0194"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310317820","host_organization_name":"Karger Publishers","host_organization_lineage":["https://openalex.org/P4310317820"],"host_organization_lineage_names":["Karger Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neuroendocrinology","raw_type":"journal-article"},{"id":"pmid:20829632","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/20829632","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neuroendocrinology","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307778","display_name":"Novartis","ror":"https://ror.org/02f9zrr09"},{"id":"https://openalex.org/F4320310388","display_name":"Novartis Pharmaceuticals Corporation","ror":"https://ror.org/028fhxy95"},{"id":"https://openalex.org/F4320322100","display_name":"Korea Electrotechnology Research Institute","ror":"https://ror.org/03ctacd45"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":18,"referenced_works":["https://openalex.org/W1529179362","https://openalex.org/W1984025513","https://openalex.org/W2001077013","https://openalex.org/W2007392362","https://openalex.org/W2026489860","https://openalex.org/W2061962280","https://openalex.org/W2062122986","https://openalex.org/W2082275755","https://openalex.org/W2086873419","https://openalex.org/W2099447985","https://openalex.org/W2105695548","https://openalex.org/W2118708995","https://openalex.org/W2123601063","https://openalex.org/W2147573461","https://openalex.org/W2167895760","https://openalex.org/W2168487042","https://openalex.org/W2168906621","https://openalex.org/W4211186562"],"related_works":["https://openalex.org/W2099447985","https://openalex.org/W2083384949","https://openalex.org/W2088668080","https://openalex.org/W1967476221","https://openalex.org/W2100438980","https://openalex.org/W2324643472","https://openalex.org/W2133418708","https://openalex.org/W2087358904","https://openalex.org/W1985189871","https://openalex.org/W2017843023"],"abstract_inverted_index":{"Cushing's":[0,3,22,96,117,205,233,256],"disease":[1,23,234],"is":[2,35,192,195,214],"syndrome":[4],"caused":[5],"by":[6,82],"an":[7,25,53],"adrenocorticotropic":[8],"hormone-secreting":[9,75],"pituitary":[10,76],"adenoma":[11],"and,":[12],"in":[13,54,92,110,148,168,202,251],"the":[14,93,196,237,252],"absence":[15],"of":[16,95,104,120,132,211,216,221,240,255],"adequate":[17],"treatment,":[18],"can":[19],"be":[20,90,166],"fatal.":[21],"represents":[24],"unmet":[26],"medical":[27,32,253],"need,":[28],"with":[29,41,49,112,204,232],"no":[30],"approved":[31],"therapies.":[33],"Pasireotide":[34],"a":[36,99,144,174,227],"novel":[37],"multi-receptor-targeted":[38],"somatostatin":[39],"analogue":[40],"high":[42],"affinity":[43,57],"for":[44,63,72],"sst(1,2,3)":[45],"and":[46,60,66,69,84,159,185,191,243],"sst(5).":[47],"Compared":[48],"octreotide,":[50],"pasireotide":[51,88,105,161,181],"has":[52],"vitro":[55],"binding":[56],"40-,":[58],"30-":[59],"5-fold":[61],"higher":[62,167],"sst(5,)":[64],"sst(1)":[65],"sst(3),":[67],"respectively,":[68],"2-fold":[70],"lower":[71],"sst(2).":[73],"Adrenocorticotropic":[74],"adenomas":[77],"predominantly":[78],"express":[79],"sst(5),":[80],"followed":[81],"sst(2)":[83],"sst(1),":[85],"suggesting":[86],"that":[87,236],"may":[89,246],"effective":[91],"treatment":[94,254],"disease.":[97,206,257],"In":[98],"15-day":[100],"phase":[101,177,199],"II":[102],"trial":[103],"600":[106,182],"\u03bcg":[107,183,187],"s.c.":[108],"b.i.d.":[109,184,188],"patients":[111,122,203,231],"de":[113],"novo":[114],"or":[115],"persistent/recurrent":[116],"disease,":[118],"22":[119],"29":[121],"(76%)":[123],"achieved":[124,135,140],"reduced":[125],"urinary":[126],"free":[127],"cortisol":[128,150],"(UFC)":[129],"levels,":[130],"5":[131],"whom":[133],"(17%)":[134],"normalized":[136,141],"UFC.":[137],"Patients":[138],"who":[139,153],"UFC":[142,217],"had":[143],"significantly":[145],"greater":[146],"reduction":[147],"serum":[149],"than":[151],"those":[152],"did":[154],"not":[155],"(p":[156],"=":[157],"0.04),":[158],"minimum":[160],"plasma":[162],"concentrations":[163],"appeared":[164],"to":[165],"responders.":[169],"Based":[170],"on":[171,229],"these":[172],"results,":[173],"randomized,":[175],"double-blind":[176],"III":[178,200],"study":[179,201,213,228],"comparing":[180],"900":[186],"was":[189],"initiated":[190],"ongoing.":[193],"This":[194],"largest":[197],"ever":[198],"The":[207],"primary":[208],"end":[209],"point":[210],"this":[212],"normalization":[215],"after":[218],"6":[219],"months":[220],"treatment.":[222],"Finally,":[223],"preliminary":[224],"results":[225],"from":[226],"17":[230],"suggest":[235],"combined":[238],"use":[239],"pasireotide,":[241],"cabergoline":[242],"low-dose":[244],"ketoconazole":[245],"have":[247],"additive":[248],"beneficial":[249],"effects":[250]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2044656399","counts_by_year":[{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":4},{"year":2015,"cited_by_count":3},{"year":2014,"cited_by_count":3},{"year":2013,"cited_by_count":7},{"year":2012,"cited_by_count":3}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2016-06-24T00:00:00"}
